Comparing two treatment plans for rectal cancer in adults 75 and older
Part of Cancer clinical trials.
This trial tests two different treatment strategies for older adults with rectal cancer that hasn't spread. The goal is to find which approach works better and is safer for people in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 75 years old or older.
- You have been diagnosed with rectal cancer (adenocarcinoma) that has not spread to other parts of the body.
- You are generally in good health (able to care for yourself and be active).
- Your tumor is located within 10 cm of the anal margin (as measured by MRI).
- You have not had prior chemotherapy or surgery for rectal cancer.
- You have adequate organ function (kidney, liver, blood counts) and are approved by a geriatric specialist.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two approaches to treating rectal cancer in people age 70 and older who have not yet had surgery. One approach gives chemotherapy and radiation before surgery, and the other adds more chemotherapy after radiation. The goal is to find which plan works better with fewer side effects.
This Phase 2 trial compares a pre-surgery (neoadjuvant) treatment plan versus the standard plan for people with stage II–III rectal cancer. The goal is to see which approach works better and is safe before surgery.
This study compares two ways of giving radiation therapy for advanced rectal cancer, combined with a chemotherapy pill and an immunotherapy drug. One approach uses a shorter course of radiation before surgery, and the other uses a longer course; researchers want to see which is more effective and safer.
This trial compares two different chemotherapy combinations given before radiation or surgery for high-risk locally advanced rectal cancer. One arm is more intense, and the other is standard. The goal is to see which works better at shrinking the tumor and possibly avoiding surgery.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
Hear when a new Locally Advanced Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.